<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00093405</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000387952</org_study_id>
    <secondary_id>MSKCC-04082</secondary_id>
    <secondary_id>NCI-6479</secondary_id>
    <nct_id>NCT00093405</nct_id>
  </id_info>
  <brief_title>17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer</brief_title>
  <official_title>A Phase II Study Of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG)In Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as 17-N-allylamino-17-demethoxygeldanamycin, work&#xD;
      in different ways to stop tumor cells from dividing so they stop growing or die.&#xD;
      17-N-allylamino-17-demethoxygeldanamycin may also stop the growth of tumor cells by blocking&#xD;
      the enzymes necessary for their growth.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well 17-N-allylamino-17-demethoxygeldanamycin&#xD;
      works in treating patients with metastatic kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the efficacy of 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) in patients&#xD;
           with metastatic papillary or clear cell renal cell carcinoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the safety of this drug in these patients.&#xD;
&#xD;
        -  Correlate tumor c-met expression with response in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is an open-label study. Patients are stratified according to histology&#xD;
      (papillary vs clear cell).&#xD;
&#xD;
      Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 60-90 minutes on&#xD;
      days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 1 year in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 3 weeks and then every 3 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24-74 patients (12-37 per stratum) will be accrued for this&#xD;
      study within 6-20 months (clear cell stratum) and 2-5 years (papillary stratum).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy (complete and partial response)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tanespimycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed renal cell carcinoma&#xD;
&#xD;
               -  Papillary OR clear cell histology&#xD;
&#xD;
                    -  If other histologies are present, clear cell or papillary must be&#xD;
                       predominant&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques&#xD;
                  OR ≥ 10 mm by spiral CT scan&#xD;
&#xD;
          -  No brain metastases unless previously treated with radiotherapy or surgery AND&#xD;
             asymptomatic with no active brain metastases detectable by CT scan or MRI for ≥ 6&#xD;
             months&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No severe valvular disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No severe debilitating pulmonary disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No allergy to egg or egg products&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biological composition to 17-N-allylamino-17-demethoxygeldanamycin (17-AAG)&#xD;
&#xD;
          -  No active or ongoing infection requiring IV antibiotics&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No more than 1 prior cytokine-based regimen&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  No more than 1 prior non-cytokine-based regimen&#xD;
&#xD;
          -  No other prior systemic treatment regimens&#xD;
&#xD;
          -  No other concurrent cytotoxic therapy&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gnanamba V. Kondagunta, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ronnen EA, Kondagunta GV, Ishill N, Sweeney SM, Deluca JK, Schwartz L, Bacik J, Motzer RJ. A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs. 2006 Nov;24(6):543-6.</citation>
    <PMID>16832603</PMID>
  </results_reference>
  <verification_date>November 2005</verification_date>
  <study_first_submitted>October 6, 2004</study_first_submitted>
  <study_first_submitted_qc>October 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2004</study_first_posted>
  <last_update_submitted>June 21, 2013</last_update_submitted>
  <last_update_submitted_qc>June 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>clear cell renal cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

